# Marie L. A. Schuttelaar

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/marie-l-a-schuttelaar/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,286 |
| Field | Contact Dermatitis and Allergies |
| h-index | 48 |
| i10-index | 177 |
| Last Known Institution | University Medical Center Groningen |
| OpenAlex ID | https://openalex.org/A5089092834 |
| ORCID iD | 0000-0002-0766-4382 |
| Works | 325 |

## Researcher papers

- [Guidelines for diagnosis, prevention, and treatment of hand eczema](https://scholariq.org/papers/guidelines-for-diagnosis-prevention-and-treatment-of-hand-eczema/)
- [Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study](https://scholariq.org/papers/dupilumab-shows-long-term-safety-and-efficacy-in-patients-with-moderate-to/)
- [Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting](https://scholariq.org/papers/towards-global-consensus-on-outcome-measures-for-atopic-eczema-research-results/)
- [Proactive disease management with 0·03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study](https://scholariq.org/papers/proactive-disease-management-with-0-03-tacrolimus-ointment-for-children-with/)
- [The European baseline series in 10 European Countries, 2005/2006 – Results of the European Surveillance System on Contact Allergies (ESSCA)](https://scholariq.org/papers/the-european-baseline-series-in-10-european-countries-2005-2006-results-of-the/)
- [The European baseline series and recommended additions: 2019](https://scholariq.org/papers/the-european-baseline-series-and-recommended-additions-2019/)
- [Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)](https://scholariq.org/papers/report-from-the-fifth-international-consensus-meeting-to-harmonize-core-outcome/)
- [Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis](https://scholariq.org/papers/goblet-cell-scarcity-and-conjunctival-inflammation-during-treatment-with/)
- [Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry](https://scholariq.org/papers/dupilumab-is-very-effective-in-a-large-cohort-of-difficult-to-treat-adult-atopic/)
- [Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial](https://scholariq.org/papers/safety-and-efficacy-of-pimecrolimus-in-atopic-dermatitis-a-5-year-randomized/)
- [Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry](https://scholariq.org/papers/rapid-and-sustained-effect-of-dupilumab-on-work-productivity-in-patients-with/)

## Researcher topics

- [Contact Dermatitis and Allergies](https://scholariq.org/topics/contact-dermatitis-and-allergies/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Occupational exposure and asthma](https://scholariq.org/topics/occupational-exposure-and-asthma/)

## Researcher university

- [University Medical Center Groningen](https://scholariq.org/institutions/university-medical-center-groningen/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.